Wilson Disease Drugs Market size was over USD 625.2 Million in 2023 and is anticipated to reach USD 1.06 Billion by the end of 2036, witnessing around 4.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of wilson disease drugs is assessed at USD 648.83 Million. The growth of the market can be attributed to the increasing prevalence of Wilson’s disease across the globe, especially in isolated areas. Wilson’s disease is caused by the mutation of the ATP7B gene which is passed on by parents to the child. This disease was observed to occur in 30,000 to 40,0000 people across the globe.
The advent of various organizations and associations in recent years, such as the Wilson Disease Association, an organization that endorses research and clinical investigations for Wilson disease and spreads awareness regarding the latest happening on the symptoms and treatment of Wilson disease, are observed to hike the market growth over the forecast period. Furthermore, the rising introduction of patient assistance programs which provides considerable growth opportunities to the companies for the development of novel therapeutic drugs for the treatment of Wilson disease is also anticipated to significantly propel the growth of the global Wilson disease drugs market during the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.2% |
|
Base Year Market Size (2023) |
USD 625.2 Million |
|
Forecast Year Market Size (2036) |
USD 1.06 Billion |
|
Regional Scope |
|
Indication (Hepatic, Neurological, Ophthalmic, Psychiatric)
The global Wilson disease drugs market is segmented and analyzed for demand and supply by indication into hepatic, neurological, ophthalmic, and psychiatric. Out of these types of indications, the neurological segment is estimated to gain the largest market share in the year 2036. Wilson’s disease includes a higher number of neurological indications such as dysarthria (difficulty in speaking), dysphagia (difficulty in swallowing), tremors, poor coordination, spasticity, involuntary movements, muscle rigidity, dystonic posture, and others. Apart from that, the surge in neurological conditions and usage of neurology devices across the globe has also spurred the demand for medical drugs to cure or manage these diseases which are also expected to propel the growth of the segment over the upcoming decades. For instance, based on the statistics released by Pan American Health Organization (PAHO), it was stated that in 2019, nearly 533,172 people died owing to neurological conditions across the globe, out of which, 320,043 were women while 213,129 were men.
Drug Type (Chelating Agents, Zinc, Tetrathiomolybdate)
The global Wilson disease drugs market is also segmented and analyzed for demand and supply by drug type into chelating agents, zinc, tetrathiomolybdate, and others. Amongst these segments, the chelating agents’ segment is expected to garner a significant share in the year 2036. Chelating agents include trientine, penicillamine, and dimercaprol which are helpful in reducing the levels of copper in blood and tissues when administered for a prolonged time period. These agents are further helpful in preventing the gathering of copper and injuries from Wilson disease. Chelating agents are developed to flush toxic metals out of the body. Toxic metals are known to cause immune system dysfunction, nervous systems disorders, cancer, birth defects, skin lesions, vascular damage, and many more. A surge in the nervous system disorder and cancer can be observed across the globe which is expected to hike the segment growth over the forecast period. As of 2020, nearly 10 million people lost their lives worldwide.
Our in-depth analysis of the global market includes the following segments:
|
By Indication |
|
|
By Drug Type |
|
|
By End-User |
|
North American Market Forecast
The North American Wilson disease drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the presence of leading market players in the region which manufacture and distribute Wilson disease drugs. Moreover, support from the government in the implementation of advanced healthcare technologies, coupled with the rise in the number of patients with hereditary disorders and Wilson’s disease in the region is anticipated to drive the demand for Wilson disease drugs in the region over the forecast period. For instance, it was estimated that in the United States, in every 30,000 individuals, one of them suffers from Wilson’s disease. Additionally, the surge in the geriatric population in this region and growing awareness among people of Wilson’s disease is also anticipated to expand the market size over the forecast period.
APAC Market Statistics
The Asia Pacific Wilson disease drugs market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market is backed by a rise in awareness about this rare disorder along with the increase in healthcare expenditure in the region during the forecast period. The developing economies in the region, especially the countries such as China, India, and Japan, are further anticipated to provide significant opportunities for the manufacturing of Wilson disease drugs, and in turn, drive the growth of the market in the region. In Asia Pacific, many key manufacturers are observed to invest a significant amount of money in R&D activities to find new drugs. Hence, all these factors are anticipated to influence the market growth positively over the forecast period.
Alexion Pharmaceuticals, Inc. made an announcement regarding the acquisition of LogicBio Therapeutic, Inc. The acquisition took place to accelerate the growth of Alexion Pharmaceuticals in developing genomic medicines using the unique technology of LogicBio.
Kadmon Holdings, Inc. announced that its generic Trientine Hydrochloride Capsules USP, 250 mg, which is a chelating agent used for the treatment of Wilson’s disease in patients who are intolerant of penicillamine, has been approved by the U.S. Food and Drug Administration (FDA).
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?